Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Giron

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|December 2, 2022
Human galectin-9 promotes the expansion of HIV reservoirs in vivo in humanized miceZhe Yuan, Leila B Giron, Colin Hart, et al.
The Journal of Infectious Diseases|March 6, 2025
Compromised Intestinal Barrier Resilience to Disruption in People with HIVMaliha W Shaikh, Shalini Singh, Leila B Giron, et al.
AIDS (London, England)|January 24, 2020
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpointLeila B Giron, Emmanouil Papasavvas, Livio Azzoni, et al.
Journal of Leukocyte Biology|April 11, 2018
Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapySurya Kumari Vadrevu, Irena Trbojevic-Akmacic, Andrew V Kossenkov, et al.
Cell Reports|August 7, 2020
Sialyl-Lewis<sup>X</sup> Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during TherapyFlorent Colomb, Leila B Giron, Leticia Kuri-Cervantes, et al.
Nature Communications|December 13, 2025
HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killingShalini Singh, S M Shamsul Islam, Rui Liu, et al.
Mbio|February 24, 2021
Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment InterruptionLeila B Giron, Emmanouil Papasavvas, Xiangfan Yin, et al.
International Journal of Antimicrobial Agents|August 9, 2019
Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trialRicardo Sobhie Diaz, Iart Luca Shytaj, Leila B Giron, et al.
AIDS (London, England)|July 18, 2020
Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individualsLeila B Giron, Livio Azzoni, Xiangfan Yin, et al.
Ebiomedicine|August 23, 2020
Interferon-α alters host glycosylation machinery during treated HIV infectionLeila B Giron, Florent Colomb, Emmanouil Papasavvas, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|December 2, 2022
Human galectin-9 promotes the expansion of HIV reservoirs in vivo in humanized miceZhe Yuan, Leila B Giron, Colin Hart, et al.
The Journal of Infectious Diseases|March 6, 2025
Compromised Intestinal Barrier Resilience to Disruption in People with HIVMaliha W Shaikh, Shalini Singh, Leila B Giron, et al.
AIDS (London, England)|January 24, 2020
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpointLeila B Giron, Emmanouil Papasavvas, Livio Azzoni, et al.
Journal of Leukocyte Biology|April 11, 2018
Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapySurya Kumari Vadrevu, Irena Trbojevic-Akmacic, Andrew V Kossenkov, et al.
Cell Reports|August 7, 2020
Sialyl-Lewis<sup>X</sup> Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during TherapyFlorent Colomb, Leila B Giron, Leticia Kuri-Cervantes, et al.
Nature Communications|December 13, 2025
HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killingShalini Singh, S M Shamsul Islam, Rui Liu, et al.
Mbio|February 24, 2021
Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment InterruptionLeila B Giron, Emmanouil Papasavvas, Xiangfan Yin, et al.
International Journal of Antimicrobial Agents|August 9, 2019
Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trialRicardo Sobhie Diaz, Iart Luca Shytaj, Leila B Giron, et al.
AIDS (London, England)|July 18, 2020
Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individualsLeila B Giron, Livio Azzoni, Xiangfan Yin, et al.
Ebiomedicine|August 23, 2020
Interferon-α alters host glycosylation machinery during treated HIV infectionLeila B Giron, Florent Colomb, Emmanouil Papasavvas, et al.
Pageof 6